Biocon Limited Q2 FY26 Concall Decoded: Debt dumped, biosimilars booming, and insulin finally getting political

---

1. Opening Hook

Just when skeptics were getting comfortable calling Biocon a “long-term story” (read: forever waiting), Q2 FY26 arrived with a clean balance sheet flex and biosimilars firing on all cylinders. Goldman Sachs exited, Kotak packed up, Edelweiss queued for the door—and suddenly margins remembered how to expand.

Between five biosimilar launches, U.S. FDA approvals, and California turning into Biocon’s insulin pilot market, this concall sounded less like damage control and more like quiet confidence. Even better, management didn’t promise miracles—just execution, scale, and patience.

Of course, generics are still warming up, CRDMO stayed boring (as planned), and insulin pricing remains a political sport. But for once, Biocon didn’t need excuses.

Read on—this one had substance, not just science.

---

2. At a Glance

• Revenue ₹4,296 cr (+20% YoY) – Biosimilars did the heavy lifting, again.
• Core EBITDA ₹1,218 cr (+23% YoY) – Debt relief therapy clearly working.
• EBITDA Margin 28% – Finance costs blinked first.
• Reported EBITDA ₹928 cr (+29% YoY) – Operating leverage finally showing up.
• PAT ₹85 cr – Profits returned after a long sabbatical.
• Interest savings ₹300 cr (FY27) – The real blockbuster is deleveraging.

---

3. Management’s Key Commentary

“We have strengthened our balance sheet by settling structured debt.”
(Translation: Expensive money is officially unemployed 😏)

“Biosimilars delivered 25% YoY growth.”
(Translation: This is no longer a pipeline story.)

“We launched bUstekinumab, bAspart, bBevacizumab, bAflibercept.”
(Translation: One launch every time an analyst blinked.)

“bDenosumab received U.S. FDA approval.”
(Translation: Another big molecule unlocked 🔓)

“California partnership enables affordable insulin access.”
(Translation: Politics met pricing, Biocon showed up.)

“Full benefit of interest savings visible from FY27.”
(Translation: EPS upgrade committee, please assemble.)

---

4. Numbers Decoded

Source table

Segment	Q2 FY26 Revenue	What’s Really Happening
Biosimilars	₹2,721 cr (+25%)	Scale + launches = margin magic
Generics	₹774 cr (+24%)	New launches rescuing P&L
CRDMO (Syngene)	₹911 cr (+2%)	Stable, predictable, boring (good)
Group EBITDA	₹928 cr	Debt exit doing the trick
R&D Spend	7% of revenue	Pipeline still being fed

Bottom line: Biosimilars are now carrying both growth and profitability.

---

5. Analyst Questions – Decoded

• How big can Insulin Aspart get?
  → Slow, responsible rollout now; real scale in CY26.
• FDA removing Phase III trials—good or risky?
  → Cuts cost, speeds launches; favors experienced players like Biocon.
• Why generics